ACCESS
EU-JAMRAI2 aims to provide substantial assistance to Member States (MS) in the development and periodic updating of their National Action Plans (NAPs) on Antimicrobial Resistance (AMR). By offering direct and significant support, the initiative seeks to enhance the capacity of MS to effectively tackle AMR within their healthcare systems. Secondly, EU-JAMRAI2 endeavors to bolster the responsiveness and coordination of health systems across the Union, thereby safeguarding individuals from the threat of AMR. Through improved collaboration and streamlined efforts, the initiative aims to fortify the resilience of healthcare systems against the proliferation of drug-resistant infections.
One of the main objectives of EU-JAMRAI2 in this field is to improve access to selected AMR-related products both for human and veterinarian use:


Focus products
The participating countries in EU-JAMRAI 2 that are working on strengthening access have identified clinically important antibiotics and veterinary vaccines with a vulnerable supply. The products reflect the national context in terms of clinical needs, availability and resistance situation. Products may change during the project.
Please click on a turquoise country to see the national focus products.
France
Amoxicillin, clavulanic acid (human)
Aztreonam (human)
Benzathine benzylpenicillin (human)
Cefixime (human)
Fosfomycin (human)
Phenoxymethylpenicillin (human)
Rifampicin (human)
Rifampicin, isoniazid (human)
Rifampicin, isoniazid, pyrazinamide (human)
Rifapentine (human)
Sulfamethoxazole, trimethoprim (human)
Vaccine for turkey rhinotracheitis virus (Veterinary)
Vaccine for clostridium related diseases in ruminant (Veterinary)
Vaccines for Muscovy ducks against Derszy disease ± parvovirosis (Veterinary)
Spain
Amikacin (human)
Aztreonam (human)
Benzathine phenoxymethylpenicillin (human)
Cefadroxil (human)
Trimetoprim and Sulfamethoxazole (human)
Oxytetracycline (veterinary)
Vaccines for hemorrahagic enteritis in turkeys (veterinary)
Vaccines for respiratory disease complex in cattle/sheep/goats (veterinary)
Vaccines for coccidiosis (veterinary)
Belgium
Cefadroxil OR Cefalexin (human)
Daptomycin (human)
Phenoxymethylpenicillin (human)
Procaine-benzylpenicillin OR Benzathine Benzylpenicillin (human)
Rifampicin (human)
Sulfadiazine (human)
Sulfamethoxazole + trimethoprim (human)
Thiamphenicol (human)
Amoxicillin (veterinary)
Cefalexin (veterinary)
Bulgaria
Amphotericin B “liposomal” (human)
Benzylpenicillin (human)
Ceftaroline (human pediatric only)
Daptomycin (human)
Eravacycline (human)
Erythromycin (human)
Fosfomycin (human)
Nitrofurantoin (human)
Phenoxymethylpenicillin (human)
Tobramycin (human)
Denmark
Flucloxacillin (human, pediatric)
Fosfomycin (human)
Nitrofurantoin (human)
Pivmecillinam (human)
Ampicillin (human and veterinay)
Benzylpenicillin (/procaine benzylpenicillin) (human and veterinary)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Rifampicin (human and veterinary)
Amoxicillin (veterinary)
Fucidic acid (veterinary)
Sulfadiazine, Trimethoprim (veterinary)
Finland
Amoxicillin (Human)
Benzylpenicillin sodium (Human)
Nitrofurantoin (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Cloxacillin (veterinary)
ERM vaccine for fish (veterinary)
Gentamicin (veterinary)
Phenoxymethylpenicillin (veterinary)
Procaine benzylpenicillin (veterinary)
Trimethoprim, Sulfonamide (veterinary)
Iceland
Amoxicillin (human and veterinary)
Amoxicillin and beta-lactamase inhibitor (human and veterinary)
Benzylpenicillin / Procaine benzylpenicillin (human and veterinary)
Cefalexin (human and veterinary)
Dicloxacillin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Sulfamethoxazole and trimethoprim / Sulfadiazine and trimethoprim (human and veterinary)
Clindamycin (veterinary)
Enrofloxacinum (veterinary)
Oxytetracycline ( veterinary)
Italy
Amikacin (human)
Azithromycin (human)
Benzathine benzylpenicillin (human)
Chloramphenicol (human)
Clarithromycin (human)
Piperacillin, tazobactam (human)
Netherlands
Amoxicillin (Human)
Amoxicillin, clavuanic acid (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicillin (Human)
Cefazolin (Human)
Ceftazidim (Human)
Ciprofloxacin (Human)
Clindamycin (Human)
Cotrimoxazol (Human)
Doxycycline (Human)
Metronidazole (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Innovative vaccines against emerging and novel animal diseases (veterinary)
Norway
Benzylpenicillin (human)
Dicloxacillin (human)
Doxycycline (human)
Erythromycin or clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human)
Phenoxymethylpenicillin (human)
Pivmecillinam (human)
Spectinomycin. (Human)
TB antibiotics from WHO guidelines (human)
Procaine benzylpenicillin (veterinary)
Salmon vaccines (veterinary)
Poland
Azithromycin (Human)
Aztreonam (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicilin natrium (Human)
Cefalexin (Human)
Flucloxacillin (Human)
Minocycline (Human)
TB antibiotics from WHO guidelines (Human)
Slovenia
Amoxicillin (human)
Cefuroxime (human)
Clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human)
Tuberculosis antibiotics (human)
Vaccination for dengue (human)
Vaccine for erysipelothrix (Veterinary)
Sweden
Amoxicillin (human)
Ceftibuten (human)
Cefixime (human)
Colistin (human)
Phenoxymethylpenicillin (human)
Procaine benzylpenicillin (veterinary)
Rifampicin (human)
Temocillin (human)
Trimethoprim, sulfamethoxazole (human)
Trimethoprim, sulfadiazine (veterinary)
Malta
Amoxicillin (human)
Aztreonam (human)
Cefalexin (human)
Cefazolin (human)
Clindamycin (human)
Co-trimoxazole (human)
Fosfomycin (human)
Temocillin (human)
Oxytetracycline (Veterinary)
Vaccine for bovine parainfluenza virus, bovine respiratory syncytial virus and pasteurella (Veterinary)
Vaccine for bovine rotavirus, bovine coronavirus and escherichia (Veterinary)
Latvia
Aztreonam (Human)
Daptomycin (Human)
Fosfomycin (Human)
Phenoxymethylpenicillin (Human)
Pivmecillinam (Human)
TB antibiotics from WHO guideline (Human)
Antibiotic assessment guide
Here you find the methodology that was applied by the countries to identify their focus products for human use (the veterinary methodology will be added here shortly).

Barriers to access
For the focus products participants will identify and analyse the specific barriers to access, within their national contexts, in collaboration with national and European stakeholders.

Targeted interventions
Targeted at the barriers to access, participating countries aim to identify, develop and support the implementation national, regional, and European interventions to strengthen access to the specific focus products.

New Products
When it comes to strengthening access to new technologies, like novel antibiotics and bacteriophages, EU-JAMRAI 2 are aiming to assist DG HERA and other European bodies in their efforts and serve as a discussion forum for these questions.
Read the conference report from our kick-off event, “Sustainable implementation of human phage therapy across the EU”, held in Brussels, Belgium on March 1st, 2024.
Marketed antibiotics for tuberculosis in EU/EEA countries and UK
This spreadsheet contains an extract of the Article 57 database received from EMA with information up to July 27, 2025. This may be helpful for those individuals procuring antibiotic for tuberculosis to better understand which products are marketed, where they are marketed, under which regulatory pathway, and the contact information for the marketing authorization holder.
Please note that the terms below apply.
- The information provided is based on data held in the Article 57 database. This data is submitted by holders of marketing authorisations (MAHs) for medicines in the European Union and the European Economic Area. The provided data reflects the state of the Article 57 database on 27 July 2025 as extracted on 28 July 2025.
- A medicinal product may contain multiple pharmaceutical products (administrable pharmaceutical forms), e.g. tablets and film-coated tablets, or tablets with different compositions as part of a same medicinal product. These forms are listed in sequence and separated by a “|” sign.
- MAHs must submit information to the European Medicines Agency (EMA) on authorised medicines and keep this information up-to-date in accordance with EU pharmaceutical regulation.
- The following Guidance can be consulted for more information on how and when Article 57 data elements are to be populated: Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2) of Regulation (EC) No. 726/2004, Chapter 3.II: XEVPRM User Guidance.
- Further information on the Article 57 database can be found here.
Webinars AND PRESENTATIONS
Regulatory pathways for unregistered medicines, evidence from tuberculosis antibiotics for human use
September 12, 2025
First step in a Journey. Developing a National At Risk Medicine List
June 3, 2025
Efforts to shift GP prescribing in Malta to narrower spectrum antibiotics
February 13, 2025
How do companies forecast anticipated demand?
October 11, 2024
Individual dispensing of antibiotics in the Netherlands
September 16, 2024
Evidence for use of narrow(er) spectrum antibiotics in primary care
June 19, 2024